UroToday and PRIMR Announce Strategic Partnership to Enhance Clinical Trial Awareness

By: David Grew MD MPH

By combining forces, the two companies aim to assist clinical trial principal investigators and sponsors in amplifying awareness of their studies, ultimately driving increased patient enrollment and engagement.

∗ ∗ ∗

[Reno, Nev.,, March 5, 2024] - UroToday - GU Oncology Today® brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology and PRIMR, the foremost oncology clinical trial patient education company, are thrilled to announce their strategic partnership aimed at revolutionizing clinical trial awareness and education.

This partnership brings together UroToday's extensive communications network, reaching both patients and providers, with PRIMR's hallmark simple doctor-created educational style. By combining forces, the two companies aim to assist clinical trial principal investigators and sponsors in amplifying awareness of their studies, ultimately driving increased patient enrollment and engagement.

UroToday boasts a massive global audience of urologists and healthcare professionals, providing unparalleled access to medical communities worldwide. PRIMR's expertise lies in crafting easily digestible educational content tailored to patients and healthcare providers, simplifying complex medical concepts and facilitating informed decision-making.

"We are excited to join forces with PRIMR to empower both patients and providers with valuable educational resources related to oncology clinical trials," said Gina Carithers, Founder and CEO of UroToday. "This partnership aligns with our mission to advance urological care through education and collaboration."

Through this collaboration, PRIMR will leverage UroToday's robust distribution channels to disseminate educational materials directly to patients and providers interested in genitourinary oncology clinical trials. This strategic approach aims to bridge the gap between patients and trial sponsors, facilitating informed participation and enhancing patient-centered care.

"We are delighted to partner with UroToday to expand the reach of our educational initiatives and support oncology clinical trial awareness," remarked David Grew MD MPH, founder of PRIMR. "Together, we will empower patients with knowledge and enable healthcare providers to make informed decisions regarding clinical trial referrals."

The partnership between UroToday and PRIMR represents a significant step forward in advancing patient education and enhancing clinical trial awareness within the oncology community. By combining their respective strengths, the two companies are poised to drive positive change and improve outcomes for patients and healthcare providers alike.

For more information about UroToday and PRIMR, visit respective websites or reach out to their dedicated teams.

‍

Other Posts

This image represents the thumbnail for the blog entitled The Untapped Potential of a Century-Old Treatment: Reviving Low-Dose Radiation Therapy for Osteoarthritis

The Untapped Potential of a Century-Old Treatment: Reviving Low-Dose Radiation Therapy for Osteoarthritis

This blog tackles the underutilized option of low-dose radiation for treating osteoarthritis in the US, a method widely ignored due to entrenched medical norms and pervasive radiophobia, despite its potential benefits and minimal side effects. It explores the history, efficacy, and misconceptions surrounding this treatment, advocating for its consideration among suitable patients who do not respond well to conventional therapies.

The thumbnail above represents the blog entitled Navigating the Evolving Landscape of Informed Consent in Clinical Trials: Draft FDA Guidance and the PRIMR Approach

Navigating the Evolving Landscape of Informed Consent in Clinical Trials: Draft FDA Guidance and the PRIMR Approach

The blog explores the transformative potential of the recent FDA guidance on informed consent processes. It highlights how PRIMR's innovative approach to patient education exemplifies the FDA's vision for a more accessible and engaging informed consent experience in clinical trials.

This image thumbnail represents the strategic partnership between UroToday and PRIMR for the blog announcement.

UroToday and PRIMR Announce Strategic Partnership to Enhance Clinical Trial Awareness

UroToday & PRIMR partner to boost clinical trial awareness in genitourinary oncology, merging UroToday's global network with PRIMR's educational content. Aimed at increasing patient enrollment, this collaboration will make trial information accessible, bridging gaps between patients & trials.